APRI (Aprinoia Therapeutics) Construction In Progress: $0.40 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Construction In Progress?

Aprinoia Therapeutics APRI Construction In Progress is $0.40 Mil as of Dec. 2023.

Aprinoia Therapeutics's quarterly construction in progress declined from Dec. 2022 ($0.35 Mil) to Jun. 2023 ($0.00 Mil) but then increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($0.40 Mil).

Aprinoia Therapeutics's annual construction in progress increased from Dec. 2021 ($0.27 Mil) to Dec. 2022 ($0.35 Mil) and increased from Dec. 2022 ($0.35 Mil) to Dec. 2023 ($0.40 Mil).

Aprinoia Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Construction In Progress Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Construction In Progress
0.27 0.35 0.40

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Construction In Progress 0.27 0.00 0.35 0.00 0.40

Aprinoia Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.40 Mil mean?
Aprinoia Therapeutics (APRI) has a Construction In Progress of $0.40 Mil as of Dec. 2023. Construction in Progress records the amount of construction work that is not complete. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Construction In Progress too high?
Aprinoia Therapeutics' current Construction In Progress is $0.40 Mil.
How does Aprinoia Therapeutics' Construction In Progress compare to ?
Aprinoia Therapeutics' Construction In Progress of $0.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Construction In Progress is $0.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Construction In Progress of $0.40 Mil. The current Construction In Progress is $0.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Construction In Progress is $0.40 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.